LED Imaging Announces New Appointment and Imaging Software
Industry leader to support LED Imaging in the orthodontic market; Company launches its own imaging software for digital imaging products
About LED DentalLED Dental is a wholly owned subsidiary of LED Medical Diagnostics Inc. Founded by the creator of the award-winning VELscope® tissue fluorescence visualization technology, LED Dental now also features the LED Imaging division that provides dentists and oral health specialists with advanced diagnostic imaging products and software. Backed by an experienced leadership team dedicated to a higher level of service and support, LED Dental products seamlessly integrate into dental practices. The company is committed to providing dental practitioners with the best technology available by identifying and adding strong products to its growing portfolio. For more information, call 888.541.4614 or visit www.leddental.com.
About LED Medical Diagnostics Inc.Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc. is a leading developer of LED?based visualization technologies for the medical industry. The company designs and manufactures the VELscope® Vx Enhanced Oral Assessment System, the first system in the world to apply tissue fluorescence visualization technology to the oral cavity. Available through major dental supply distributors, the VELscope® Vx is used to conduct more screenings for oral cancer and other oral diseases than any other adjunctive device. LED Medical Diagnostics is currently listed on the Toronto Stock Exchange (TSX-V) under the symbol "LMD," the OTCQX under the symbol "LEDIF," as well as the Frankfurt Stock Exchange under the symbol "LME." For more information, visit www.ledmd.com.
Forward Looking Statement
This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information include statements regarding, but not limited to the Company's future growth strategy for the United States, its distribution strategy and product offerings, potential expansion of the Company's technology to other medical applications or markets, or the potential introduction of new technologies by the Company. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation's actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to competition risks, distributor risks, product development risks such as regulatory, design, intellectual property and other factors described in the Corporation's reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2013. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.